Stock Spotlight: Medtronic Plc (NYSE:MDT)

About Medtronic Plc

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems and sensors, and InPen, a smart insulin pen. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.

Source: EODHD

Key Stats

Source: EODHD. Data as of 10/06/26.

Growth Potential

• Leader in the medical-device/therapy space with the company remaining one of the largest and most diversified medical technology companies, spanning cardiovascular, neurosurgery, diabetes, surgical robotics and more with nature of products (implantable devices, surgical technologies, chronic-disease therapies) giving it exposure to structural tailwinds (aging populations, rising chronic disease, growing global healthcare access) making demand more resilient and less cyclical.
• Significant balance sheet liquidity increases flexibility to undertake strategic M&A (focus on tuck-in M&A to support strong market positions) and R&D.
• Solid shareholder returns via dividends which have increased for the 48th consecutive year.
• Market Innovation and portfolio transformation create growth optionality with the company developing and launching new technologies, such as its pulsed-field ablation (PFA) systems for cardiac arrhythmias, and its upcoming surgical-robotics platform (Hugo) while also spinning off its diabetes business (expected in 2026) to better focus resources on higher-margin and faster-growing segments.
• Margin expansion and operational leverage with management remaining focused on driving margin improvement (improving gross margins, streamlining operations, improving supply chain efficiency).
  

Key Risks

• Aggressive competition by other established players putting pressure on margins.
• Strict government regulations and scrutiny.
• IP theft by countries like China.
• Challenging political environments with U.S.-China trade war and Brexit.
• Downturn in the U.S. economy given the fact that the company still derives 51% of its revenue from the local market.
• Currency headwinds.